Chemicals and stemcells combined have advanced regenerative medicine with few safety concerns, focusing on improving techniques and treatment effectiveness.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stemcells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.